Diabetic Macular Edema

This treatment is already approved for both diabetic macular edema (DME) and NIU-PS outside the US, including in 17 European countries.

Hashad is a retinal specialist with over 25 years of leadership experience in global research and development.

Additionally, the prognosis of macular edema may help clinicians evaluate renal function, investigators reported

Visual acuity with both approaches was comparable and the device was efficacious and safe.

This database could enhance the workflow of eye care professionals with its in-depth reference data for retinal layer thickness and optic nerve head metrics.

Apellis Pharmaceuticals and EyePoint Pharmaceuticals are both scheduled to present at the conference.

A look at the current state of AI in diabetic eye disease and where the future may take us.

Ramiro Ribeiro, MD, PhD, shares insights from the ongoing research tyrosine kinase inhibitors for AMD and DME.

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a one-time, outpatient procedure, continuously delivering a customized formulation of ranibizumab over time.

The main outcomes were the measurements of the visual acuity and visual field defects.

ARCATUS or ARVN001, in Greater China, South Korea, Australia, New Zealand, India and the ASEAN Countries is formally known as XIPERE in the United States and was developed by Clearside Biomedical.

The new funding will allow the company to complete its ongoing Phase 2 trial of proprietary nanomedicine, migaldendranib, in patients with wet AMD and DME

The objective of this trial was to evaluate safety and tolerability and identify dose level for further evaluation.

This phase 2b study (ASPIRE) is currently underway.

In October, Oxular began a phase 2 trial for its therapeutic candidate OXU-001, for treatment of diabetic macular edema

A Helsinki University Hospital study found diabetes, glycemic control, or insulin therapy did not significantly affect anatomical or functional outcomes after epiretinal membrane surgery.

Curacle plans to finalize its development strategy, including phase 2b and 3 trials, through a Type C meeting with the US FDA in February of 2025.

The PFS is approved for treatment of neovascular age-related macular degeneration, diabetic macular edema and macular edema following retinal vein occlusion.

The researchers conducted a retrospective study to assess serum inflammatory biomarkers in patients with different subtypes of diabetic macular edema (DME).

The report is titled, Diabetic Macular Edema Market Insights, Epidemiology, and Market Forecast-2034.

Study participants include people with no diabetes as well as those with various stages of the condition, creating a set of information distinct from previous research.

Optical coherence tomography will be in all eye care services by October 2025

This announcement establishes Boehringer as the first pharmaceutical company to join the MTM Vision Consortium.

To educate the public—including parents, caregivers, and allied health professionals—Prevent Blindness is offering free educational resources, including fact sheets, social media graphics, web pages, and educational videos in both English and Spanish.

The Gr8 Eye Movement campaign by Prevent Blindness and Regeneron emphasizes the critical role of caregivers in eye health, revealing significant gaps in caregivers' awareness of retinal diseases and aging-related vision loss.

The company reported that Duravyu 2.7mg demonstrated an early and sustained anatomical improvement mirroring BCVA results with a 68 micron reduction in CST. Full topline data is anticipated in Q1 of 2025.

The researchers identified 12 eyes of 7 patients (mean age, 73.3 years; 4 women) with noninfectious IOI after intravitreal faricimab injections.

David Eichenbaum, MD and Riad Sherif, MD, CEO of Oculis will present the updates with additional info on topline results from the ACUITY Phase 2 trial of OCS-05 for the treatment of acute optic neuritis (AON).